ZEISS Vision Care | ISO Meeting

Aalen, Germany | 08 July 2026 | ZEISS Vision Care

Defining important international standards for spectacle lenses and other ophthalmic products
Diverse and global expertise: ZEISS experts represented their countries and different ZEISS business units

From June 8 to 12, 2026, ZEISS employee and ISO Officer Timo Kratzer chaired the most recent ISO/TC 172/SC 7 Meeting on Ophthalmic Optics held in Milan. Chairman Kratzer, Head of Academic & Public Health Ecosystems at ZEISS Vision Care, and a total of about 100 ophthalmic industry experts discussed and developed international standards for eye care, vision correction, and eye surgery. Topics and outcomes of the meetings will soon be disclosed with the publication of new and updated standards by the International Organization for Standardization (ISO).

Defining important international standards for spectacle lenses and other ophthalmic products

The objective of ISO’s subcommittee “SC 7 – Ophthalmic Optics and Instruments” is to balance industry advancement with robust safeguards, so consumers can benefit from the most innovative eye care solutions without compromising their eye health. To ensure this, the subcommittee creates standardized terminology, testing methods, and manufacturing requirements for spectacle frames and lenses, material standards and care accessories for contact lenses, implants (e.g., intraocular lenses and other optical/non-optical eye implants) as well as precision tools and diagnostic devices used by eye care professionals.

Diverse and global expertise: ZEISS experts represented their countries and different ZEISS business units

Through the nominations, experts from ZEISS represented their respective countries, such as Germany, Australia, the USA, Italy, and China, as well as different ZEISS Segments and Strategic Business Units. Together with the other industry participants, ZEISS experts engaged in different project and working groups. The groups focused mainly on contact lenses, spectacle lenses, ophthalmic instruments, and intraocular lenses, with numerous resolutions advancing new and revised standards for safety, performance, testing, and labeling. These developments reflect significant regulatory and technological progress across both consumer and clinical ophthalmic products.

Different ZEISS employees have served as chairmen since the founding of ISO TC 172/SC 7. With profound knowledge of the human eye and visual behavior, ZEISS experts actively drive progress and innovation in their field, as they are also committed to protecting and improving the vision and lifelong visual health of the world’s consumers.

_{ZEISS is either a trademark or a registered trademark of Carl Zeiss AG.}

Press contact Frederic Vuillermin International PR: Eyeglass Lenses, Coatings and Materials

ZEISS Vision Care

About ZEISS

ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling almost 12 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology, and Consumer Markets (September 30, 2025).

For its customers, ZEISS develops, produces, and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses, and binoculars.

With a portfolio aligned with future growth areas like digitalization, healthcare, and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 14 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.

With over 47,400 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 30 production facilities worldwide (March 31, 2026). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.

Further information at www.zeiss.com

ZEISS Vision Care

ZEISS Vision Care, part of ZEISS Consumer Markets segment, develops and manufactures comprehensive solutions for the entire value chain of ophthalmic optics. The portfolio includes top-quality eyeglass lenses, partner programs, ophthalmic instruments, services, digital solutions and apps for both eye care professionals and consumers, as well as care products for the eye and beyond. As one of the world's leading manufacturers of eyeglass lenses, ZEISS is focused on optimal visual comfort and individualized vision solutions. With a passion for innovation and quality, ZEISS Vision Care is committed to protecting and enhancing people's vision and contributing to lifelong visual health.

Download

Press Release ISO Meeting

From June 8 to 12, 2026, ZEISS employee and ISO Officer Timo Kratzer chaired the most recent ISO/TC 172/SC 7 Meeting on Ophthalmic Optics held in Milan.

156 KB

Download